RxDoctor Payments Data

Lauri Greis

Nurse Practitioner · Las Cruces, NMNPI 1356334999

Payments from drug & device makers

$648in general payments, 2019–2025

Across 28 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$306
  • GSK$113
  • AbbVie$107
  • Lilly USA, LLC$45
  • Boehringer Ingelheim$26
  • Alnylam Pharmaceuticals Inc.$23
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$648 in reported general payments places this provider in the 80th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$123
Medicare patients
12
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone41$58,709
OzempicSemaglutide36$50,661
JardianceEmpagliflozin26$37,052
MounjaroTirzepatide27$29,188
TrulicityDulaglutide15$23,954
FarxigaDapagliflozin Propanediol15$22,739
EliquisApixaban15$16,995
Aimovig AutoinjectorErenumab-Aooe12$11,499
Clonidine41$6,452
Estradiol31$2,995
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,401
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,108
Atorvastatin Calcium176$1,973
Gabapentin74$1,931
Levothyroxine Sodium163$1,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$306$58,70941 claims
Lilly USA, LLCMounjaro, Trulicity$45$53,14242 claims
Boehringer IngelheimJardiance$26$37,05226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →